VEGFA and neoplasm: These tumor types respond differently to anti-angiogenic therapy and the use of the vascular endothelial growth factor A (VEGFA) blocking agent bevacizumab is currently applied only in metastatic CRC [32,33,34], further highlighting the key role of the TME in the regulation of tumor angiogenesis and the therapy response.